Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical investigation

• Publication date

  2013-12-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.4155/CLI.13.96
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

  2019cited by this paper
• Rifaximin therapy and hepatic encephalopathy: Pros and cons.

  2012cited by this paper
• Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.

  2012cited by this paper
• Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

  2012cited by this paper
• The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Rifaximin therapy for patients with irritable bowel syndrome without constipation.

  2011cited by this paper
• Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease Activity

  2010cited by this paper
• Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation

  2010cited by this paper
• Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

  2010cited by this paper
• Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells.

  2010cited by this paper
• Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

  2010cited by this paper
• Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.

  2010cited by this paper
• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

  2010cited by this paper
• Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.

  2010cited by this paper
• Use and Safety of Rifaximin in Children With Inflammatory Bowel Disease

  2009cited by this paper
• Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles

  2009cited by this paper
• Rifaximin pharmacology and clinical implications

  2009cited by this paper
• Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

  2008cited by this paper
• Microbial influences in inflammatory bowel diseases.

  2008cited by this paper
• Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator

  2007cited by this paper
• Rifaximin for the treatment of active pouchitis: A randomized, double‐blind, placebo‐controlled pilot study

  2007cited by this paper
• Inflammatory bowel disease: Progress and current concepts of etiopathogenesis

  2007cited by this paper
• Unravelling the pathogenesis of inflammatory bowel disease

  2007cited by this paper
• The effects of NOD2/CARD15 mutations on the function of the intestinal barrier.

  2007cited by this paper
• Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic

  2006cited by this paper
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

  2006cited by this paper
• Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo‐controlled trial with rifaximin

  2006cited by this paper
• Rifaximin for active ulcerative colitis.

  2006cited by this paper
• BACTERIAL INTERACTIONS WITH CELLS OF THE INTESTINAL MUCOSA: TOLL-LIKE RECEPTORS AND NOD2

  2005cited by this paper
• Clinical Approach to Diseases of Ileal Pouch-Anal Anastomosis

  2005cited by this paper
• An open-label evaluation of rifaximin in the treatment of active Crohn's disease*

  2005cited by this paper
• Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

  2005cited by this paper
• 2004 drug approval highlights: FDA update.

  2005cited by this paper
• Self inflicted rectal ulcer: hearing is believing

  2003cited by this paper
• Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis

  2003cited by this paper
• Preliminary Study of Ciprofloxacin in Active Crohn's Disease

  2002cited by this paper
• Mucosal flora in inflammatory bowel disease.

  2002cited by this paper
• Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease

  2002cited by this paper
• Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.

  2001cited by this paper
• A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.

  2001cited by this paper
• Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

  1999cited by this paper
• Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis

  1999cited by this paper
• A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease

  1999cited by this paper
• Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.

  1998cited by this paper
• Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.

  1998cited by this paper
• Rifaximin systemic absorption in patients with ulcerative colitis

  1998cited by this paper
• Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease.

  1998cited by this paper
• A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.

  1997cited by this paper
• An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.

  1996cited by this paper
• Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.

  1991cited by this paper
• Double blind, placebo controlled trial of metronidazole in Crohn's disease.

  1991cited by this paper
• A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial.

  1987cited by this paper
• Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.

  1986cited by this paper
• Peripheral neuropathy in Crohn's disease patients treated with metronidazole.

  1985cited by this paper
• Antibiotic therapy for treatment in relapse of intestinal Crohn's disease

  1985cited by this paper
• A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result.

  1982cited by this paper
• A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations.

  1982cited by this paper
• Metronidazole in Crohn's disease. A double blind cross-over clinical trial.

  1978cited by this paper

• Fecal microbiota transplantation for ulcerative colitis-where to from here?

  2019cites this paper